Developer docs
API playgroundTry for free, no card

Search company profiles

Syapse

Full company profile

uuid0000jxk

Namestring
Syapse
Legal namestring
Syapse
Websiteurl
syapse.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Syapse is a healthcare technology company that built and operates a Learning Health Network aggregating de-identified real-world clinical data from community oncology providers to generate evidence for precision medicine, drug development, and clinical decision support. The company appears to have evolved its commercial identity toward the N-Power Medicine brand, whose platform centers on three core products: the Kaleido Registry (a consented prospective data collection program with 12,000+ enrolled patients and a 95% consent rate), N-Power Prospective External Controls (purpose-built comparator cohorts mirroring targeted trial protocols for phase II-III decision making), and the N-Power Community Trial Accelerator (a research-ready network enabling systematic pre-screening and signal-based site activation). The underlying technology combines an AI-enabled human-in-the-loop platform with a point-of-care solution that integrates with any EHR without disrupting physician workflow, holding HIPAA, HITRUST CSF, ISO 27001, and ISO 9001 certifications.

Syapse monetizes this platform through enterprise B2B contracts with two primary customer segments: biopharmaceutical companies, which purchase real-world evidence and prospective external control cohorts to de-risk oncology drug development, and community oncology providers, which gain access to clinical decision support, research participation, and operational savings (reported at 5-10 hours per physician per week). Pricing is quote-based and not publicly disclosed, but the recurring, contract-based nature of biopharma engagements and the network-participation model with providers point to a subscription- and services-oriented revenue mix. The company was founded in 2008, is headquartered in San Francisco, operates with 51-100 employees, and has raised approximately $222.6 million in cumulative venture and growth funding across nine disclosed rounds since 2011, most recently a $35 million growth investment led by Innovatus Capital Partners in July 2022.

Short descriptiontext

Syapse (operating commercially as N-Power Medicine) operates an oncology Learning Health Network and clinical research platform, selling real-world evidence, prospective external controls, and trial acceleration services to biopharmaceutical companies and community oncology providers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
real-world evidence, precision medicine analytics, oncology data platform, clinical research network, healthcare data analytics
Industry1 code
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
NAICS code3 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Other Scientific and Technical Consulting Services54169
SIC code2 codes
  • Services-Misc Health & Allied Services, Nec8090
  • Services-Computer Processing & Data Preparation7374
Product category
Real-World Evidence Platform
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Real-World Evidence Analytics Services
TypeSubscription Recurring
Description

Syapse generates revenue by providing real-world evidence services to biopharmaceutical companies and healthcare providers through its Learning Health Network. The company aggregates clinical data from provider networks and offers analytics services to support precision medicine initiatives, drug development, and clinical decision-making.

globenewswire.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Syapse operates a Learning Health Network that aggregates real-world clinical, molecular, and outcomes data from community oncology providers to generate real-world evidence (RWE). The company sells data-driven products and platform capabilities to biopharmaceutical companies for clinical development and to healthcare providers for point-of-care decision support in precision oncology.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

N-Power Medicine offers a clinical research platform built on a novel single workflow that makes routine care and research one and the same. The core product portfolio includes the Kaleido Registry (a prospective data collection program with 12,000+ patients enrolled), N-Power Prospective External Controls (purpose-built comparator cohorts for phase II-III decision making), and N-Power Community Trial Accelerator (a research-ready network enabling rapid trial enrollment). These are powered by a Human-in-the-Loop Platform combining AI automation with expert human oversight, and a Point-of-Care Technology Solution that integrates with existing EHR systems.

Product and service1 record
1Kaleido Registry
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Syapse partners with healthcare providers (hospitals, cancer centers, oncology practices) through its Learning Health Network. Providers contribute de-identified clinical data and in return gain access to real-world evidence analytics and the ability to participate in clinical research initiatives.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Syapse serves biopharmaceutical companies by providing real-world evidence generated from its Learning Health Network. These partnerships support precision medicine initiatives, clinical trial design, and post-market surveillance for pharmaceutical therapies.

Peers10 records
TypeDirect peer
Description

An oncology-specific real-world evidence and EHR company acquired by Roche for $1.9B. It is the most direct competitor to Syapse, offering oncology data analytics, clinical trial support, and RWE services to biopharma, with a similarly large provider network.

2Tempus
TypeDirect peer
Description

A precision medicine company combining genomic sequencing, AI-driven analytics, and a large oncology data library to support drug development and clinical care. Tempus competes directly with Syapse in providing RWE and molecular data to biopharma clients and providers.

TypeDirect peer
Description

An oncology real-world evidence and AI company serving both biopharma and providers with synthetic control arms, trial design, and provider data networks. It is a head-to-head competitor in the oncology RWE market Syapse serves.

TypeDirect peer
Description

An oncology-focused real-world data and analytics company that partners with providers and biopharma to generate RWE for clinical and commercial decisions. COTA competes in the same oncology RWE and clinical trial support market as Syapse.

TypeBroad incumbent
Description

A molecular profiling and genomic data company (owned by Roche) that combines comprehensive genomic testing with a large clinico-genomic database. While broader in scope, it competes with Syapse in oncology RWE and precision medicine data for biopharma.

TypeBroad incumbent
Description

A leading clinical trial technology platform (part of Dassault Systèmes) offering electronic data capture, trial design, and increasingly RWE capabilities. Medidata competes with Syapse in the clinical trial enablement and data analytics space for biopharma sponsors.

TypeBroad incumbent
Description

A global CRO and healthcare data powerhouse that operates at scale across clinical trial operations, RWE, and commercial analytics. IQVIA is a broad incumbent with overlapping capabilities to Syapse's clinical research support and real-world evidence services.

8Deep 6 AI
TypeEmerging player
Description

An AI-powered clinical trial matching and patient recruitment platform that mines EHR data to surface eligible patients. Deep 6 overlaps with Syapse's Community Trial Accelerator in helping biopharma sponsors identify and enroll patients in oncology trials.

9nference
TypeEmerging player
Description

An AI-driven biomedical data analytics company that synthesizes real-world clinical, molecular, and biomedical literature data for biopharma R&D. nference overlaps with Syapse in providing AI-enabled real-world evidence for drug development, particularly in oncology.

10Oracle Health (Cerner)
TypeBroad incumbent
Description

A major EHR and healthcare data platform that provides population-level clinical data infrastructure, including research and analytics capabilities. As a broad incumbent with deep hospital and oncology clinic penetration, Oracle Health represents both a potential partner and competitive threat to Syapse's provider data network strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Syapse

Real-World Evidence Platformsyapse.com

Syapse (operating commercially as N-Power Medicine) operates an oncology Learning Health Network and clinical research platform, selling real-world evidence, prospective external controls, and trial acceleration services to biopharmaceutical companies and community oncology providers.

What Syapse does

Syapse is a healthcare technology company that built and operates a Learning Health Network aggregating de-identified real-world clinical data from community oncology providers to generate evidence for precision medicine, drug development, and clinical decision support. The company appears to have evolved its commercial identity toward the N-Power Medicine brand, whose platform centers on three core products: the Kaleido Registry (a consented prospective data collection program with 12,000+ enrolled patients and a 95% consent rate), N-Power Prospective External Controls (purpose-built comparator cohorts mirroring targeted trial protocols for phase II-III decision making), and the N-Power Community Trial Accelerator (a research-ready network enabling systematic pre-screening and signal-based site activation). The underlying technology combines an AI-enabled human-in-the-loop platform with a point-of-care solution that integrates with any EHR without disrupting physician workflow, holding HIPAA, HITRUST CSF, ISO 27001, and ISO 9001 certifications.

Syapse monetizes this platform through enterprise B2B contracts with two primary customer segments: biopharmaceutical companies, which purchase real-world evidence and prospective external control cohorts to de-risk oncology drug development, and community oncology providers, which gain access to clinical decision support, research participation, and operational savings (reported at 5-10 hours per physician per week). Pricing is quote-based and not publicly disclosed, but the recurring, contract-based nature of biopharma engagements and the network-participation model with providers point to a subscription- and services-oriented revenue mix. The company was founded in 2008, is headquartered in San Francisco, operates with 51-100 employees, and has raised approximately $222.6 million in cumulative venture and growth funding across nine disclosed rounds since 2011, most recently a $35 million growth investment led by Innovatus Capital Partners in July 2022.

Syapse firmographics

Firmographics
Name
Syapse
Legal name
Syapse
Website
https://syapse.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Syapse (operating commercially as N-Power Medicine) operates an oncology Learning Health Network and clinical research platform, selling real-world evidence, prospective external controls, and trial acceleration services to biopharmaceutical companies and community oncology providers.
Ownership category
akta.pro rank

Syapse industry classification

Industry
Product category
Real-World Evidence Platform
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169)
SIC
Services-Misc Health & Allied Services, Nec (8090), Services-Computer Processing & Data Preparation (7374)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)

Keywords

  • Real-world evidence
  • Precision medicine analytics
  • Oncology data platform
  • Clinical research network
  • Healthcare data analytics

Where Syapse is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Markets served

Syapse business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Real-World Evidence Analytics Services: Syapse generates revenue by providing real-world evidence services to biopharmaceutical companies and healthcare providers through its Learning Health Network. The company aggregates clinical data from provider networks and offers analytics services to support precision medicine initiatives, drug development, and clinical decision-making.

Go-to-market motion1 record

Distribution channels1 record

Syapse product offering

Product offering

Core offering

Syapse operates a Learning Health Network that aggregates real-world clinical, molecular, and outcomes data from community oncology providers to generate real-world evidence (RWE). The company sells data-driven products and platform capabilities to biopharmaceutical companies for clinical development and to healthcare providers for point-of-care decision support in precision oncology.

Product overview

N-Power Medicine offers a clinical research platform built on a novel single workflow that makes routine care and research one and the same. The core product portfolio includes the Kaleido Registry (a prospective data collection program with 12,000+ patients enrolled), N-Power Prospective External Controls (purpose-built comparator cohorts for phase II-III decision making), and N-Power Community Trial Accelerator (a research-ready network enabling rapid trial enrollment). These are powered by a Human-in-the-Loop Platform combining AI automation with expert human oversight, and a Point-of-Care Technology Solution that integrates with existing EHR systems.

Differentiator

Problem solved

Functional benefit

Products and services

  • Kaleido Registry

Companies that use Syapse

Customer profile

Segments2 records

Ideal customer profiles2 records

Syapse technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Syapse partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Healthcare ProviderscoreStrategic or Co-development PartnerSyapse partners with healthcare providers (hospitals, cancer centers, oncology practices) through its Learning Health Network. Providers contribute de-identified clinical data and in return gain access to real-world evidence analytics and the ability to participate in clinical research initiatives.
  • Biopharmaceutical CompaniescoreStrategic or Co-development PartnerSyapse serves biopharmaceutical companies by providing real-world evidence generated from its Learning Health Network. These partnerships support precision medicine initiatives, clinical trial design, and post-market surveillance for pharmaceutical therapies.

Scale indicators3 records

Syapse competitors and assessment

Company assessment

Direct peers

  • Flatiron Health: An oncology-specific real-world evidence and EHR company acquired by Roche for $1.9B. It is the most direct competitor to Syapse, offering oncology data analytics, clinical trial support, and RWE services to biopharma, with a similarly large provider network.
  • Tempus: A precision medicine company combining genomic sequencing, AI-driven analytics, and a large oncology data library to support drug development and clinical care. Tempus competes directly with Syapse in providing RWE and molecular data to biopharma clients and providers.
  • ConcertAI: An oncology real-world evidence and AI company serving both biopharma and providers with synthetic control arms, trial design, and provider data networks. It is a head-to-head competitor in the oncology RWE market Syapse serves.
  • COTA Healthcare: An oncology-focused real-world data and analytics company that partners with providers and biopharma to generate RWE for clinical and commercial decisions. COTA competes in the same oncology RWE and clinical trial support market as Syapse.

Broad incumbents

  • Foundation Medicine: A molecular profiling and genomic data company (owned by Roche) that combines comprehensive genomic testing with a large clinico-genomic database. While broader in scope, it competes with Syapse in oncology RWE and precision medicine data for biopharma.
  • Medidata Solutions: A leading clinical trial technology platform (part of Dassault Systèmes) offering electronic data capture, trial design, and increasingly RWE capabilities. Medidata competes with Syapse in the clinical trial enablement and data analytics space for biopharma sponsors.
  • IQVIA: A global CRO and healthcare data powerhouse that operates at scale across clinical trial operations, RWE, and commercial analytics. IQVIA is a broad incumbent with overlapping capabilities to Syapse's clinical research support and real-world evidence services.
  • Oracle Health (Cerner): A major EHR and healthcare data platform that provides population-level clinical data infrastructure, including research and analytics capabilities. As a broad incumbent with deep hospital and oncology clinic penetration, Oracle Health represents both a potential partner and competitive threat to Syapse's provider data network strategy.

Emerging players

  • Deep 6 AI: An AI-powered clinical trial matching and patient recruitment platform that mines EHR data to surface eligible patients. Deep 6 overlaps with Syapse's Community Trial Accelerator in helping biopharma sponsors identify and enroll patients in oncology trials.
  • nference: An AI-driven biomedical data analytics company that synthesizes real-world clinical, molecular, and biomedical literature data for biopharma R&D. nference overlaps with Syapse in providing AI-enabled real-world evidence for drug development, particularly in oncology.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights6 records

Customer concentration

Syapse social profiles

Digital presence

Syapse compliance and trust

Trust signal

Compliance4 records

Syapse financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Syapse leadership team

Management profile

Number of profiles

Profiles6 records

Syapse funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Syapse M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syapse

What does Syapse do?

Syapse operates a Learning Health Network that aggregates real-world clinical, molecular, and outcomes data from community oncology providers to generate real-world evidence (RWE). The company sells data-driven products and platform capabilities to biopharmaceutical companies for clinical development and to healthcare providers for point-of-care decision support in precision oncology.

Is Syapse a public or private company?

Syapse is a private company. It is classified as venture growth investor backed and is currently operating.

When was Syapse founded?

Syapse was founded in 2008. It employs 11 to 50 people.

Where is Syapse based?

Syapse is headquartered in San Francisco, United States, in the North America region.

How does Syapse make money?

One revenue line is on record: real-World Evidence Analytics Services.

Who are Syapse's main competitors?

Direct peers on record are Flatiron Health, Tempus, ConcertAI and COTA Healthcare. Broad incumbents are Foundation Medicine, Medidata Solutions, IQVIA and Oracle Health (Cerner). Emerging players are Deep 6 AI and nference.

Does Syapse have an API?

No public API is recorded for Syapse.

What industry is Syapse in?

Syapse's product category is Real-World Evidence Platform. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 54171 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TracxnTop Companies in Oncology Informatics Worldwide (Oct, 2025)The article presents a ranking of top companies in the global oncology informatics sector as of October 2025, highlighting Tempus AI, Flatiron Health, Syapse, and Personalis. It details their core technologies, such as precision medicine platforms and genomic sequencing, along with key financial metrics like funding totals and recent investment rounds.GlobeNewswireSyapse Expands Oncology Real-World Data Offerings with Introduction of Syapse Cohorts: EssentialsSyapse launched Syapse Cohorts: Essentials, a foundational real-world data offering for cancer research, complementing its Enriched tier. The dataset covers over 50 tumor types and includes de-identified patient information from health systems, labs, and registries. The company aims to support personalized cancer research and treatment.GlobeNewswireSyapse and FDA Extend Collaboration to Advance the Use of Real-World Data (RWD) and Inform Regulatory Science in OncologySyapse and the FDA Oncology Center of Excellence renewed a four-year agreement to develop research projects advancing real-world data use in oncology. The collaboration will evaluate RWD study designs, analyze Syapse's Learning Health Network data, and explore novel oncology data sources for evidence generation.HIT ConsultantSyapse and FDA OCE Collaborate to Advance Real-World Evidence in OncologySyapse and the FDA Oncology Center of Excellence renewed their four-year collaboration to advance real-world evidence in oncology. The partnership will evaluate RWD study designs, develop clinically meaningful research questions, and analyze Syapse's Learning Health Network data. It builds on prior studies on immune-checkpoint inhibitor-related pneumonitis and COVID-19 impacts.YahooSyapse and FDA Extend Collaboration to Advance the Use of Real-World Data (RWD) and Inform Regulatory Science in OncologySyapse and the FDA Oncology Center of Excellence renewed a four-year agreement to develop research projects advancing real-world data and evidence in oncology. The collaboration will evaluate RWD study designs, analyze Syapse's Learning Health Network data, and explore novel oncology data sources to inform regulatory science.GlobeNewswireSyapse and FDA Extend Collaboration to Advance the Use of Real-World Data (RWD) and Inform Regulatory Science in OncologySyapse and the FDA Oncology Center of Excellence renewed a four-year agreement to develop research projects advancing real-world data use in oncology. The collaboration will evaluate RWD study designs, analyze Syapse's Learning Health Network data, and explore novel oncology data sources for regulatory science.BioSpaceSyapse Enters Collaboration with Merck Using Real-World Evidence to Better Understand CancersSyapse and Merck (MSD) announced a collaboration outside the US and Canada to use Syapse's real-world evidence platform for cancer patients. The partnership aims to improve outcomes across multiple tumor types, focusing on the pre-diagnosis and treatment phase. Syapse's multi-source data strategy is intended to provide actionable insights for better care.GlobeNewswireSyapse Enters Collaboration with Merck Using Real-World Evidence to Better Understand CancersSyapse and Merck announced a collaboration outside the US and Canada to use Syapse's real-world evidence platform for cancer care. The partnership focuses on understanding the pre-diagnosis stage and treatment initiation across multiple tumor types. Syapse's multi-source data strategy aims to provide actionable insights for patient care.GlobeNewswireSyapse and Genesis Research Combine Forces to Offer Real-World Evidence Services and Data to Oncology InnovatorsSyapse and Genesis Research announced a strategic partnership to combine real-world evidence services for oncology innovators. The collaboration will let Genesis clients access Syapse's oncology platform and Syapse clients access Genesis's research partnerships. Both companies will begin offering co-marketed services in coming weeks.BioSpaceScience 37 and Syapse Partner to Enable Faster Patient Enrollment in Oncology Clinical TrialsScience 37 and Syapse announced a partnership to use real-world data intelligence to identify patients for oncology clinical trials, aiming to speed enrollment. The collaboration targets the enrollment stage, which causes delays in roughly four-fifths of trials and costs sponsors up to $20 million per month.